经颅磁刺激辅助认知行为治疗惊恐障碍的疗效及影响因素研究

注册号:

Registration number:

ChiCTR1800020109 

最近更新日期:

Date of Last Refreshed on:

2018-12-14 22:30:47 

注册时间:

Date of Registration:

2018-12-14 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

经颅磁刺激辅助认知行为治疗惊恐障碍的疗效及影响因素研究

Public title:

TMS for panic disorder

注册题目简写:

English Acronym:

研究课题的正式科学名称:

经颅磁刺激辅助认知行为治疗惊恐障碍的疗效及影响因素研究

Scientific title:

Therapeutic effect and influencing factors of transcranial magnetic stimulation assisted cognitive behavioral therapy for panic disorder

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

杨祥云 

研究负责人:

杨祥云 

Applicant:

Yang Xiangyun 

Study leader:

Yang Xiangyun 

申请注册联系人电话:

Applicant telephone:

+86 18810628917

研究负责人电话:

Study leader's
telephone:

+86 18810628917

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

wysun828@126.com

研究负责人电子邮件:

Study leader's E-mail:

wysun828@126.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市西城区德外大街安康胡同5号

研究负责人通讯地址:

北京市西城区德外大街安康胡同5号

Applicant address:

5 Ankang Lane, Dewai Street, Xicheng District, Beijing, China

Study leader's address:

5 Ankang Lane, Dewai Street, Xicheng District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

首都医科大学附属北京安定医院

Applicant's institution:

Beijing Anding Hospital, Capital Medical University

研究负责人所在单位:

首都医科大学附属北京安定医院

Affiliation of the Leader:

Beijing Anding Hospital, Capital Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

(2018)科研第(79)号-2018113FS-2

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

首都医科大学附属北京安定医院伦理委员会

Name of the ethic committee:

Ethics Committee of Beijing Anding Hospital Affiliated to Capital Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2018-12-03 00:00:00

伦理委员会联系人:

贾京津

Contact Name of the ethic committee:

Jia Jingjin

伦理委员会联系地址:

北京市西城区德外大街安康胡同5号

Contact Address of the ethic committee:

5 Ankang Lane, Dewai Street, Xicheng District, Beijing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

首都医科大学附属北京安定医院

Primary sponsor:

Beijing Anding Hospital, Capital Medical University

研究实施负责(组长)单位地址:

北京市西城区德外大街安康胡同5号

Primary sponsor's address:

5 Ankang Lane, Dewai Street, Xicheng District, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京市

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京安定医院

具体地址:

北京市西城区德外大街安康胡同5号

Institution
hospital:

Beijing Anding Hospital, Capital Medical University

Address:

5 Ankang Lane, Dewai Street, Xicheng District, Beijing, China

经费或物资来源:

北京市科委

Source(s) of funding:

Beijing Science and Technology Commission

研究疾病:

惊恐障碍  

Target disease:

panic disorder

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

治疗新技术临床试验 

Study phase:

New Treatment Measure Clinical Study

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

1.探讨在认知行为治疗惊恐障碍的早期联合应用低频重复经颅磁刺激治疗的效果;2.分析影响低频重复经颅磁刺激辅助认知行为治疗惊恐障碍的疗效的因素。  

Objectives of Study:

1.To explore the effect of early combined application of low frequency repetitive transcranial magnetic stimulation(LFRTMS) in cognitive behavioral therapy for panic disorder. 2.To analyze the factors influencing the efficacy of low frequency repetitive transcranial magnetic stimulation (LFRTMS) combined with CBT in the treatment of panic disorder.

药物成份或治疗方案详述:

本研究纳入惊恐障碍患者50例,随机分配到研究组和病例对照组各25例,同时纳入25名正常人作为正常对照。研究组接受12周认知行为治疗,并在1-4周接受TMS真刺激。病例对照组同样接受12周认知行为治疗,在1-4周接受TMS伪刺激。在0,2,4,6,8,10,12周分别评估患者的惊恐障碍严重程度、焦虑情绪、抑郁情绪等临床现象,所有患者及正常对照在基线及12周末分别接受功能磁共振成像扫描。正常对照组无任何干预。 

Description for medicine or protocol of treatment in detail:

Fifty patients with panic disorder were enrolled in this study. They were randomly assigned to study group and case control group, 25 normal persons as normal control group. The study group received 12 weeks of cognitive behavioral therapy and 1-4 weeks of real TMS stimulation. The case control group also received 12 weeks of cognitive behavioral therapy and 1-4 weeks of pseudo-stimulation of TMS. At 0, 2, 4, 6, 8, 10 and 12 weeks, the severity of panic disorder, anxiety, depression and other clinical phenomena of all patients were assessed. All patients and normal controls underwent functional magnetic resonance imaging at baseline and 12 weeks respectively. There was no intervention in the normal control group.  

纳入标准:

Inclusion criteria

排除标准:

排除标准:
Ⅰ. 根据研究者判断,患者具有自杀或伤害他人的危险;
Ⅱ. 具有脑器质性疾病和重大躯体疾病史;
Ⅲ. 符合精神分裂症、双相情感障碍等其它精神障碍诊断;
Ⅳ. 具有药物依赖及精神活性物质使用证据;
Ⅴ. 既往接受过电休克、经颅磁刺激、深部脑刺激等影响脑功能的治疗的患者;
Ⅵ. 体内有金属植入物及金属义齿者,处于孕期、哺乳期,有幽闭恐惧症等不能行MRI扫描者。

Exclusion criteria:

1. According to the judgement of researchers, patients are at risk of suicide or injury to others;
2. History of brain organic diseases and major somatic diseases;
3. Conformity with other mental disorders such as schizophrenia and bipolar affective disorder;
4. Evidence of drug dependence and use of psychoactive substances;
5. Patients who have received electroconvulsive, transcranial magnetic stimulation, deep brain stimulation and other treatments affecting brain function in the past;
6. Those who have metal implants and dentures in vivo are in pregnancy and lactation, and have claustrophobia and other persons who can not be scanned by MRI.

研究实施时间:

Study execute time:

From 2018-03-12 00:00:00 To 2021-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2018-12-30 00:00:00 To 2021-06-30 00:00:00

干预措施:

Interventions:

组别:

研究组

样本量:

25

Group:

Group 2

Sample size:

干预措施:

认知行为治疗联合TMS真刺激

干预措施代码:

Intervention:

Cognitive Behavior Therapy Combined with True Stimulation of TMS

Intervention code:

组别:

病例对照组

样本量:

25

Group:

Group 1

Sample size:

干预措施:

认知i行为治疗联合TMS伪刺激

干预措施代码:

Intervention:

Cognitive behavioral therapy combined with TMS pseudostimulus

Intervention code:

组别:

正常对照组(不随机)

样本量:

25

Group:

normal control group (not randomized)

Sample size:

干预措施:

无干预

干预措施代码:

Intervention:

non

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京市 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京安定医院 

单位级别:

三级甲等专科医院 

Institution
hospital:

Beijing Anding Hospital, Capital Medical University

Level of the institution:

Tertiary A Hospital

测量指标:

Outcomes:

指标中文名:

惊恐障碍严重程度量表

指标类型:

主要指标

Outcome:

Panic Disorder Severity Scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

汉密尔顿17项抑郁量表

指标类型:

主要指标

Outcome:

Hamilton Depression Rating Scale

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

汉密尔顿焦虑量表

指标类型:

主要指标

Outcome:

Hamilton Anxiety Scale, HAMA

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

临床疗效总评量表

指标类型:

次要指标

Outcome:

Clinical global impression, CGI

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

症状自评量表

指标类型:

次要指标

Outcome:

SCL-90

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

个人和社会功能量表

指标类型:

次要指标

Outcome:

Personal and Social Performance Scale, PSP

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

满意度评价(视觉模拟评分法

指标类型:

次要指标

Outcome:

VAS

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

治疗副反应量表

指标类型:

副作用指标

Outcome:

Treatment Emergent Symptom Scale,TESS

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良反应量表

指标类型:

副作用指标

Outcome:

Udvalg for Kliniske Undersogelser, UKU

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良事件记录表

指标类型:

副作用指标

Outcome:

Adverse Event Record Table

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

治疗副反应量表

指标类型:

副作用指标

Outcome:

Treatment Emergent Symptom Scale,TESS

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

不良反应量表

指标类型:

副作用指标

Outcome:

Udvalg for Kliniske Undersogelser, UKU

Type:

Adverse events

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

颅脑磁共振成像

组织:

Sample Name:

brain MRI

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由不参与本研究的工作人员应用随机数字表产生随机序列。

Randomization Procedure (please state who generates the random number sequence and by what method):

Random sequences are generated by random number tables by staff who are not involved in this study

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

未说明

Blinding:

Not stated

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

EpiData 数据库

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

EpiData database

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表, epidata数据库

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form and EpiData database

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2018-12-14 22:30:47